BioSpace News Archive

Shattuck Labs, Inc. announced the pricing of a registered offering of 4,651,163 shares of common stock, par value $0.0001, at a price of $6.45 per share, which is priced at the closing price on Nasdaq for the common stock on December 20, 2023.

SomaLogic, Inc. issued an open letter to stockholders highlighting the value maximizing merger entered into with Standard BioTools on October 4, 2023.

Fauna Bio today announced a multi-year agreement with Eli Lilly and Company to apply Fauna’s Convergence™ artificial intelligence (AI) platform to support preclinical drug discovery efforts in obesity.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer and President, and Tasos Konidaris, Chief Financial Officer, will participate in the 42nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024.

Equillium, Inc. (Nasdaq: EQ) today announced an update on multi-cytokine programs EQ101 in development for the treatment of alopecia areata, EQ102 in development for the treatment of celiac disease, and EQ302, a new orally delivered multi-cytokine inhibitor.

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, recently launched aPAP ClearPath™, a new serum-based blood test that can be used by physicians in the U.S. to obtain a definitive diagnosis of aPAP, a rare autoimmune lung disease mediated by autoantibodies targeting GM-CSF.

SELLAS Life Sciences Group, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for SLS009, the Company’s novel and highly selective CDK9 inhibitor, for the treatment of relapsed/refractory (r/r) Peripheral T-cell Lymphomas (PTCL).

Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs for cancer, announced today the publication of extensive preclinical data on SON-1210 in Frontiers in Immunology.

Apnimed, Inc. today announced the first patient dosed in its SynAIRgy Phase 3 study designed to examine the efficacy and safety of AD109 (aroxybutynin/atomoxetine) compared to placebo at six-months.

RenovoRx, Inc today announced the expansion of their clinical development pipeline in preparation for the commencement of a second Phase III trial.